Valneva SE (XBUL:AYJ)
лв 2.078 0 (0%) Market Cap: 580.89 Mil Enterprise Value: 669.08 Mil PE Ratio: 0 PB Ratio: 1.33 GF Score: 46/100

Valneva SE at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 03:30PM GMT
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Valneva, Thomas Lingelbach. Thanks for joining us today, Thomas.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Pleasure. Thank you.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're going to do a fireside chat format. So maybe to start off, for those who are new to the story, if you can provide a 1-minute intro highlighting your main products and key catalysts ahead.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Yes. So Valneva is a specialty vaccine company, focusing on the commercialization and development of vaccines in areas of high unmet medical need. We have commercial products in the field of travel vaccines. And we have 3 major advanced clinical stage assets, all of them

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot